N-Methylation as a Strategy for Enhancing the Affinity and Selectivity of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating RNA

ACS Chemical Biology

Volumn 11, Issue 1, 2016, Pages 88-94

  Hilimire, Thomas A ^a   Bennett, Ryan P ^c   Stewart, Ryan A ^c   Garcia Miranda, Pablo ^d   Blume, Alex ^d   Becker, Jordan ^e   Sherer, Nathan ^e   Helms, Eric D ^f   Butcher, Samuel E ^d   Smith, Harold C ^a,c   Miller, Benjamin L ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c OyaGen Inc   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 FRAMESHIFT STIMULATORY SIGNAL RNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; PEPTIDE; PROTEIN BINDING;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RIBOSOMAL FRAMESHIFTING; RNA BINDING; RNA METHYLATION; SURFACE PLASMON RESONANCE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; METHYLATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SYNTHESIS;

BASE SEQUENCE; FRAMESHIFTING, RIBOSOMAL; HEK293 CELLS; HIV-1; HUMANS; METHYLATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDES; PROTEIN BINDING; RNA, VIRAL; RNA-BINDING PROTEINS;

EID: 84955239134     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00682     Document Type: Article

References (44)

1. Brierley, I. (1995) Ribosomal frameshifting viral RNAs J. Gen. Virol. 76, 1885-1892 10.1099/0022-1317-76-8-1885
2. Baril, M., Dulude, D., and Gendron, K. (2003) Efficency of a programmed -1 ribosomal frameshift in the different subtypes of the HIV-1 group M RNA 9, 1246-1253 10.1261/rna.5113603
3. Shehu-Xhilaga, M., Crowe, S., and Johnson, M. (2001) Maintenance of the Gag/Gag-Pol ratio is important for HIV-1 RNA Dimerization and Viral Infectivity J. Virol. 75, 1834-1831 10.1128/JVI.75.4.1834-1841.2001
4. Nikolaitchik, O. A. and Hu, W.-S. (2014) Deciphering the role of the Gag-Pol ribosomal frameshift signal in HIV-1 RNA genome packaging J. Virol. 88, 4040-4046 10.1128/JVI.03745-13
5. Dulude, D., Berchiche, Y. A., Gendron, K., Brakier-Gingras, L., and Heveker, N. (2006) Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1 Virology 345, 127-136 10.1016/j.virol.2005.08.048
6. Staple, D. and Butcher, S. (2003) Solution Structure of the HIV-1 frameshfit inducing stem-loop RNA Nucleic Acids Res. 31, 4326-4331 10.1093/nar/gkg654
7. Staple, D. W. and Butcher, S. E. (2005) Solution structure and thermodynamic investigation of the HIV-1 frameshift inducing element J. Mol. Biol. 349, 1011-1023 10.1016/j.jmb.2005.03.038
8. Gaudin, C., Mazauric, M.-H., Traïkia, M., Guittet, E., Yoshizawa, S., and Fourmy, D. (2005) Structure of the RNA signal essential for translational frameshifting in HIV-1 J. Mol. Biol. 349, 1024-1035 10.1016/j.jmb.2005.04.045
9. Low, J. T., Garcia-Mirana, P., Mouzakis, K. D., Groelick, R. J., Butcher, S. E., and Weeks, K. M. (2014) Structure and dynamics of the HIV-1 frameshift element RNA Biochemistry 53, 4282-4292 10.1021/bi5004926
10. Biswas, P., Jiang, X., Pacchia, A. L., Dougherty, J. P., and Peltz, S. W. (2004) The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy J. Virol. 78, 2082-2087 10.1128/JVI.78.4.2082-2087.2004
11. Gareiss, P. C. and Miller, B. L. (2009) Ribosomal frameshifting: An emerging drug target for HIV Curr. Opin. Invest. Drugs 10, 121-128
12. Thomas, J. and Hergenrother, P. (2008) Targeting RNA with Small molecules Chem. Rev. 108, 1171-1224 10.1021/cr0681546
13. Guan, L. and Disney, M. (2012) Recent Advances in developing small molecules targeting RNA ACS Chem. Biol. 7, 73-86 10.1021/cb200447r
14. Blakeley, B. D., DePorter, S. M., Mohan, U., Burai, R., Tolbert, B. S., and McNaughton, B. R. (2012) Methods for identifying and characterizing interactions involving RNA Tetrahedron 68, 8837-8855 10.1016/j.tet.2012.07.001
15. Hung, M., Patel, P., Davis, S., and Green, S. R. (1998) Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication J. Virol. 72, 4819-4824
16. Marcheschi, R., Tonelli, M., Kumar, A., and Butcher, S. (2011) Structure of the HIV-1 frameshift site RNA bound to a small molecule inhibitor of viral replication ACS Chem. Biol. 6, 857-864 10.1021/cb200082d
17. Staple, D., Venditti, V., Niccolai, N., Elson-Schwab, L., Tor, Y., and Butcher, S. (2008) Guanidinoneomycin B recognition of an HIV-1 RNA helix ChemBioChem 9, 93-102 10.1002/cbic.200700251
18. McNaughton, B., Gareiss, P., and Miller, B. (2007) Identification of a selective small-molecule ligand for HIV-1 frameshift-inducing stem-loop RNA from an 11,325 member resin bound dynamic combinatorial library J. Am. Chem. Soc. 129, 11306-11307 10.1021/ja072114h
19. Ofori, L., Hilimire, T., Bennett, R., Brown, N., Smith, H., and Miller, B. (2014) High-affinity recognition of HIV-1 frameshift-stimulating RNA alters frameshifting in vitro and interferes with HIV-1 infectivity J. Med. Chem. 57, 723-732 10.1021/jm401438g
20. Athanassiou, Z., Patora, K., Dias, R. L., Moehle, K., Robinson, J. A., and Varani, G. (2007) Structure-guided peptidomimetic design leads to nanomlar β-hairpin inhibitors of the tat-TAR interaction of bovine immunodeficiency virus Biochemistry 46, 741-751 10.1021/bi0619371
21. Moehle, K., Athanassiou, Z., Patora, K., Davidson, K., Varani, G., and Robinson, J. A. (2007) Design of β-hairpin peptidomimetics that inhibit binding of α-helical HIV-1 Rev protein to the Rev Response Element RNA Angew. Chem., Int. Ed. 46, 9101-9104 10.1002/anie.200702801
22. Socha, A., LaPlante, K., Russell, D., and Rowley, D. (2009) Structure-activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming Staphyloccus aureus and Enterococcus faecalis Bioorg. Med. Chem. Lett. 19, 1504-1507 10.1016/j.bmcl.2009.01.010
23. Holladay, M., Kopecka, H., Miller, T., Bednarz, L., Nikkel, A., Bianchi, B., Witte, D., Shiosaki, K., Lin, C., Asin, K., and Nadzan, A. (1994) Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in Vitro and in Vivo CCK activity J. Med. Chem. 37, 630-635 10.1021/jm00031a013
24. Chatterjee, J., Ovadia, O., Zahn, G., Marinelli, L., Hoffman, A., Gilon, C., and Kessler, H. (2007) Multiple N-methylation by a designed approach enhances receptor selectivity J. Med. Chem. 50, 5878-5881 10.1021/jm701044r
25. Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H. A., Jelinek, R., Gilon, C., Hoffman, A., and Kessler, H. (2008) Improving oral bioavailability of peptides by multiple N-methlyation: somatostatin analgoues Angew. Chem., Int. Ed. 47, 2595-2599 10.1002/anie.200705797
26. Chatterjee, J., Mierke, D., and Kessler, H. (2008) Conformational preference and potential templates of N-methylated cyclic pentaalanine peptides Chem.-Eur. J. 14, 1508-1517 10.1002/chem.200701029
27. Chatterjee, J., Rechenmacher, F., and Kessler, H. (2013) N-methylation of peptides and proteins: an important method for modulating biological functions Angew. Chem., Int. Ed. 52, 254-269 10.1002/anie.201205674
28. Miller, S. and Scanlan, T. (1997) Site-selective N-methylation of peptides on solid support J. Am. Chem. Soc. 119, 2301-2302 10.1021/ja9635443
29. Ofori, L. O., Hoskins, J., Nakamori, M., Thornton, C. A., and Miller, B. L. (2012) From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy Nucleic Acids Res. 40, 6380-6390 10.1093/nar/gks298
30. Luedtke, N., Liu, Q., and Tor, Y. (2003) RNA-ligand interactions: affinity and specificity of aminoglycoside dimers and acridine conjugates to the HIV-1 Rev Response Element Biochemistry 42, 11391-11403 10.1021/bi034766y
31. Buttke, T., McCubrey, J., and Owen, T. (1993) Use of an aqeous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines J. Immunol. Methods 157, 233-240 10.1016/0022-1759(93)90092-L
32. 3-peptide inhibitors of p53-hDM2 complexation-correlation between affinity and cell permeability J. Am. Chem. Soc. 132, 2904-2906 10.1021/ja910715u
33. Bernal, F., Tyler, A., Korsmeye, S., Walensky, L., and Verdine, G. (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide J. Am. Chem. Soc. 129, 2456-2457 10.1021/ja0693587
34. Platt, E. J. E., Wehrly, K. K., Kuhmann, S. E. S., Chesebro, B. B., and Kabat, D. D. (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type J. Virol. 72, 2855-2864
35. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 5, 730-739 10.1038/nrd2082
36. Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., Ton, T., Li, X., Loughhead, D. G., Nunn, P. A., Karr, D. E., Gerritsen, M. E., Funk, J. O., Owens, T. D., Verner, E., Brameld, K. A., Hill, R. J., Goldstein, D. M., and Taunton, J. (2015) Prolonged and tunable residence time using reversible covalent kinase inhibitors Nat. Chem. Biol. 11, 525-531 10.1038/nchembio.1817
37. Brakier-Gingras, L., Charbonneau, J., and Butcher, S. (2012) Targeting frameshifting in the human immunodeficiency virus Expert Opin. Ther. Targets 16, 249-258 10.1517/14728222.2012.665879
38. Plant, E. P., Pérez-Alvarado, G. C., Jacobs, J. L., Mukhopadhyay, B., Hennig, M., and Dinman, J. D. (2005) A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal PLoS Biol. 3 (e172) 1012-1023 10.1371/journal.pbio.0030172
39. Falk, H., Mador, N., Udi, R., Panet, A., and Honigman, A. (1993) Two cis-acting signals control ribosomal frameshift between human T-cell leukemia virus type II gag and pro genes J. Virol. 67, 6273-6277
40. Dos Ramos, F., Carrasco, M., Doyle, T., and Brierley, I. (2004) Programmed -1 ribosomal frameshifting in the SARS coronavirus Biochem. Soc. Trans. 32, 1081-1083 10.1042/BST0321081
41. Larsen, B., Gesteland, R. F., and Atkins, J. F. (1997) Structural probing and mutagenic analysis of the stem-loop required for Escherichia coli dnaX ribosomal frameshifting: programmed efficiency of 50% J. Mol. Biol. 271, 47-60 10.1006/jmbi.1997.1162
42. Antonov, I., Coakley, A., Atkins, J. F., Baranov, P. V., and Borodovsky, M. (2013) Identification of the nature of reading frame transitions observed in prokaryotic genomes Nucleic Acids Res. 41, 6514-6530 10.1093/nar/gkt274
43. Below, A. T., Meskauskas, A., Musalgaonkar, S., Advani, V. M., Solima, S. O., Kasprzak, W. K., Shapiro, B. A., and Dinman, J. D. (2014) Ribosomal frameshifting in the CCR5 mRNA is regulated by miRNAs and the NMD pathway Nature 512, 265-269 10.1038/nature13429
44. Belew, A. T. and Dinman, J. D. (2015) Cell cycle control (and more) by programmed -1 ribosomal frameshifting: implications for disease and therapeutics Cell Cycle 14, 172-178 10.4161/15384101.2014.989123